Alto Neuroscience flags Nature Medicine trial showing pramipexole cuts anhedonia symptoms versus placebo

Alto Neuroscience, Inc.

Alto Neuroscience, Inc.

ANRO

0.00
  • Alto Neuroscience highlighted a newly published Nature Medicine trial showing pramipexole reduced anhedonia versus placebo in mood-disorder patients.
  • Benefits also showed up on separate measures of anhedonia and apathy, with effects maintained through a six-month open-label extension.
  • Post-hoc findings indicated patients with major depressive disorder improved more than those with dysthymia, pointing to a clearer target population.
  • High nausea rates in the pramipexole arm underscored tolerability limits that ALTO-207 aims to address by pairing pramipexole with ondansetron.
  • A potentially pivotal Phase 2b trial of ALTO-207 in treatment-resistant depression is ongoing, with data expected in 2H 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606150803BIZWIRE_USPR_____20260615_BW604254) on June 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.